Yarrow Bioscience, Inc.
YARW- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001566044
No open-market purchases or sales by Yarrow Bioscience, Inc. insiders were filed in the last 90 days; 46 institutions reported holding it in 13F filings for Q2 2026, worth $8.79M in total; no superinvestor holds it.
13F holders, Q4 2024
Institutional positions in Yarrow Bioscience, Inc. as of Dec 31, 2024. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 35
- +3 vs. Q3 2024
- Shares held
- 7.06M
- +412.1K (+6.2%) vs. Q3 2024
- Total value
- $23.4M
- +$10.4M (+80.1%) vs. Q3 2024
- New holders
- 9
- 10 more added
- Sold out
- 6
- 6 more reduced
1 institution that held it in Q3 2024 haven't filed for Q4 2024 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q3 2024: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting YARW on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 46 | $8.79M |
| Q1 2026 | 46 | $8.49M |
| Q4 2025 | 45 | $5.35M |
| Q3 2025 | 36 | $1.33M |
| Q2 2025 | 46 | $13.4M |
| Q1 2025 | 38 | $11.5M |
| Q4 2024 | 35 | $23.4M |
| Q3 2024 | 33 | $14.3M |
| Q2 2024 | 32 | $16.1M |
| Q1 2024 | 32 | $22.9M |
| Q4 2023 | 33 | $18.4M |
| Q3 2023 | 21 | $1.54M |
| Q2 2023 | 20 | $1.63M |
| Q1 2023 | 23 | $1.10M |
| Q4 2022 | 41 | $1.10M |
| Q3 2022 | 41 | $1.84M |
| Q2 2022 | 41 | $3.25M |
| Q1 2022 | 45 | $5.63M |
| Q4 2021 | 55 | $12.5M |
| Q3 2021 | 65 | $20.1M |
| Q2 2021 | 73 | $64.0M |
| Q1 2021 | 87 | $152.4M |
Institutions, Q4 2024
Shares, value and share of portfolio for each institution holding Yarrow Bioscience, Inc.; share changes are against Q3 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| FMR LLC | 5 | $17 | 0.00% | +5 | New |
| Wells Fargo & Company | 65 | $218 | 0.00% | 00.0% | Unchanged |
| Centerpoint Advisors, LLC | 350 | $1.00K | 0.00% | 00.0% | Unchanged |
| JPMorgan Chase & Co | 314 | $1.05K | 0.00% | +137+77.4% | Added |
| CWM, LLC | 500 | $2.00K | 0.00% | +500 | New |
| UBS Group AG | 631 | $2.11K | 0.00% | +617+4,407.1% | Added |
| MB, Levis & Associates, LLC | 1,041 | $3.49K | 0.00% | 00.0% | Unchanged |
| Tower Research Capital LLC (TRC) | 1,386 | $4.64K | 0.00% | −823−37.3% | Reduced |
| Bank of America Corp | 1,491 | $5.00K | 0.00% | −787−34.5% | Reduced |
| BFSG, LLC | 3,500 | $11.7K | 0.00% | +3,500 | New |
| Morgan Stanley | 4,299 | $14.4K | 0.00% | +2,500+139.0% | Added |
| State Street Corp | 15,765 | $52.8K | 0.00% | 00.0% | Unchanged |
| Commonwealth Equity Services, LLC | 18,298 | $61.0K | 0.00% | 00.0% | Unchanged |
| Jane Street Group, LLC | 20,286 | $68.0K | 0.00% | +20,286 | New |
| XTX Topco Ltd | 21,018 | $70.4K | 0.01% | +21,018 | New |
| Northern Trust Corp | 23,971 | $80.3K | 0.00% | −13,319−35.7% | Reduced |
| Renaissance Technologies LLC | 24,943 | $83.6K | 0.00% | −61,700−71.2% | Reduced |
| Royal Bank of Canada | 25,229 | $84.0K | 0.00% | +22,789+934.0% | Added |
| Staley Capital Advisers Inc | 36,472 | $122.2K | 0.01% | 00.0% | Unchanged |
| Bridgeway Capital Management, LLC | 36,958 | $123.8K | 0.00% | +36,958 | New |
| Prelude Capital Management, LLC | 59,400 | $199.0K | 0.02% | −5,747−8.8% | Reduced |
| Susquehanna International Group, LLP | 70,832 | $237.3K | 0.00% | +10,476+17.4% | Added |
| BlackRock, Inc. | 83,314 | $279.1K | 0.00% | +245+0.3% | Added |
| Geode Capital Management, LLC | 135,017 | $452.3K | 0.00% | +427+0.3% | Added |
| Parkman Healthcare Partners LLC | 152,973 | $512.5K | 0.07% | −50,000−24.6% | Reduced |
| Adage Capital Partners GP, L.L.C. | 154,134 | $516.3K | 0.00% | +154,134 | New |
| Schonfeld Strategic Advisors LLC | 176,658 | $591.8K | 0.00% | +8,058+4.8% | Added |
| UBS Oconnor LLC | 245,800 | $823.4K | 0.02% | +245,800 | New |
| Exome Asset Management LLC | 353,434 | $1.18M | 0.89% | 00.0% | Unchanged |
| Palo Alto Investors LP | 445,434 | $1.49M | 0.23% | 00.0% | Unchanged |
| Acorn Capital Advisors, LLC | 456,970 | $1.53M | 0.82% | +456,970 | New |
| Vanguard Group Inc | 475,129 | $1.59M | 0.00% | +31,611+7.1% | Added |
| Citadel Advisors LLC | 1,230,457 | $4.12M | 0.00% | +43,044+3.6% | Added |
| Eventide Asset Management, LLC | 1,394,336 | $4.45M | 0.08% | 00.0% | Unchanged |
| Cormorant Asset Management, LP | 1,394,336 | $4.67M | 0.26% | 00.0% | Unchanged |
| AlphaCentric Advisors LLC | 0 | $0 | 0.00% | −268,485−100.0% | Sold out |
| ADAR1 Capital Management, LLC | 0 | $0 | 0.00% | −152,865−100.0% | Sold out |
| Silverarc Capital Management, LLC | 0 | $0 | 0.00% | −76,784−100.0% | Sold out |
| Lynx1 Capital Management LP | 0 | $0 | 0.00% | −16,194−100.0% | Sold out |
| Russell Investments Group, Ltd. | 0 | $0 | 0.00% | −187−100.0% | Sold out |
| Barclays PLC | 0 | $0 | 0.00% | −100−100.0% | Sold out |
| DSC Advisors, L.P. | – | – | – | – | Not filed |